Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932904 · ClinicalTrials.gov registry record · Phase 4
Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
A Phase 4 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 4
- Development phase
- 361
- Enrollment target
NCT02932904 is a Phase 4 study that has completed, run by Takeda. The registered enrollment target is 361 participants.
The verdict
NCT02932904, a Phase 4 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 361 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of vortioxetine (10 and 20 mg, once daily) versus paroxetine (20 mg, once daily) on sexual functioning in healthy participants after 5 weeks of double-blind treatment.
Interventions
- DRUG Placebo
- DRUG Paroxetine
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2017-06-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02932904
The ClinicalTrials.gov registry entry for NCT02932904 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02932904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02932904 about?
NCT02932904 is a clinical study titled "Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers". The purpose of this study is to evaluate the effect of vortioxetine (10 and 20 mg, once daily) versus paroxetine (20 mg, once daily) on sexual functioning in healthy participants after 5 weeks of double-blind treatment.
What is the current status of trial NCT02932904?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 361 participants. The study started on 2016-11-21. Estimated completion is 2017-06-09.
What interventions are being tested in trial NCT02932904?
The interventions under investigation include: Placebo (DRUG), Paroxetine (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02932904?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.